运动员选择性雄激素受体调节剂滥用:系统综述
该系统综述纳入2003至2022年72篇文献,从运动医学角度总结选择性雄激素受体调节剂(SARMs)的临床效应、消除 profile、污染、安全性与流行率。运动员SARMs使用流行率估计为1%至3%,可致瘦体重增加及骨重塑、睾酮抑制、肝肾前列腺增大等不良反应,13篇病例报告描述15例滥用病例。
要点
- 运动员SARMs使用流行率估计为1%至3%,多数经网络购买且多被其他物质污染。
- SARMs临床前与临床研究报告瘦体重显著增加,并出现骨重塑、睾酮抑制及肾、肝、前列腺增大等副作用。
- 13篇病例报告共15例,均为男性,中位年龄32岁(范围19-52岁),8/15为运动员,均口服平均8周。
核心结论
- 该系统综述结果旨在教育运动医学临床医生与研究者更好地识别、诊断和治疗运动员SARMs滥用。
- SARMs使用与肌肉量增加、肝毒性、心脏毒性、肌腱损伤及全身雄激素样副作用相关,包括前列腺增大和血清睾酮抑制。
- 识别和治疗SARMs滥用需要详细询问物质与补充剂使用史并保持开放沟通,提供有文献支持的患者教育,协商停用SARMs,并对不良事件进行多学科治疗。
- 运动员SARMs滥用日益普遍且不安全,公共卫生监管机构应倡导对这类灰色市场化合物进行监管。
研究设计与样本
- 系统综述,证据等级4。
- 按照PRISMA指南对PubMed、Cochrane和Embase数据库的英文文献进行系统检索。
- 纳入与SARMs临床结局、消除profile、污染、安全性、流行率和兴奋剂管制相关的文章。
- 共纳入2003年至2022年的72篇文章。
主要发现
- 运动员中SARMs使用流行率估计为1%至3%。
- SARMs临床前和临床研究报告瘦体重显著增加及副作用,包括骨重塑、睾酮抑制以及肾、肝和前列腺增大。
- 13篇病例报告描述了15例SARMs滥用病例,所有患者均为男性,中位年龄32岁(范围19-52岁),超过一半为运动员(8/15),均口服SARMs,平均疗程8周。
- 病例报告中5例患者明确否认「非法药物使用」,提示患者可能认为其使用是合法的。
- 运动员最常在网上购买SARMs,其中大多数化合物已被证明被其他物质污染,导致不良反应。
临床怎么用
- 运动员报告的SARMs使用剂量远高于临床研究剂量,可能增加所报告副作用的风险,如肝损伤、胰岛素敏感性受损、心血管事件和肌腱损伤。
- 识别和治疗SARMs滥用需要详细询问物质与补充剂使用史并保持开放沟通,提供有文献支持的患者教育,协商停用SARMs,并对不良事件进行多学科治疗。
- 公共卫生监管机构应倡导对这类灰色市场化合物进行监管。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their performance-enhancing implications, SARMs are increasingly abused by athletes. To date, SARMs have no Food and Drug Administration approved use, and recent case reports associate the use of SARMs with deleterious effects such as drug-induced liver injury, myocarditis, and tendon rupture. PURPOSE: (1) To provide a comprehensive synthesis of the literature pertaining to SARMs from a sports medicine perspective and (2) to provide a better understanding of the clinical effects, treatment protocols, prevalence, and potential contamination associated with athlete-consumed SARMs. STUDY DESIGN: Systematic review; Level of evidence, 4. METHODS: A systematic review of the English-language literature from PubMed, Cochrane, and Embase databases was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Articles relevant to SARM clinical outcomes, elimination profiles, contamination, safety profiles, prevalence, and doping control were included. RESULTS: A total of 72 articles from 2003 to 2022 were identified for inclusion. The prevalence of SARM use among athletes is estimated to be 1% to 3%. SARM preclinical and clinical studies reported significant increases in lean body mass and side effects-including bone remodeling, testosterone suppression, and kidney, liver, and prostate enlargement. Thirteen case reports described 15 cases of SARM abuse. All described patients were men, with a median age of 32 years (range, 19-52 years), more than half were identified as athletes (8/15), and all ingested SARMs orally for a mean course of 8 weeks. Five patients described in the case reports explicitly denied "illicit drug use," implying patients may believe their use to be legal. Athletes most commonly purchased SARMs online, and most of these compounds have been shown to be contaminated with other substances, contributing to adverse effects. Athletes reported consuming SARMs at much higher doses than clinically studied, which may increase the risk of the reported side effects, such as liver injury, impaired insulin sensitivity, cardiovascular events, and tendon damage. CONCLUSION: The results of this systematic review serve to educate sports medicine clinicians and researchers on how to better identify, diagnose, and treat athlete SARM abuse. SARM use is associated with increased muscle mass, hepatotoxicity, cardiotoxicity, tendon damage, and androgenic side effects throughout the body-including prostate enlargement and serum testosterone suppression. Identifying and treating SARM abuse requires taking a thorough substance and supplement use history with open communication, providing literature-supported patient education, negotiating SARM discontinuation, and performing multidisciplinary treatment of adverse events. Athlete SARM abuse is increasingly widespread and unsafe, and public health oversight bodies should advocate for regulation of these gray-market compounds.
引用
- Vasireddi N, Hahamyan HA, Gould HP, et al. Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review. Am J Sports Med. 2025. PMID: 39755947. doi:10.1177/03635465241252435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。